Immunological and histological evaluation of clinical samples from psoriasis patients treated with anti-CD6 itolizumab
- 3 March 2014
- journal article
- clinical trial
- Published by Taylor & Francis in mAbs
- Vol. 6 (3) , 782-792
Abstract
Psoriasis is a chronic inflammatory disease with a prevalence of approximately 2-3% in the general population. The majority of diagnosed patients have plaque psoriasis, and about 20% have moderate-to-severe disease. Itolizumab, a new monoclonal antibody specific for the CD6 molecule mainly expressed on T lymphocytes, has demonstrated to inhibit in vitro ligand-induced proliferation and pro-inflammatory cytokine production. We assessed the immunological and histopathological effect of the antibody using clinical samples taken from 26 patients with moderate-to-severe psoriasis included in a clinical trial. The precursor frequency of lymphocytes activated with anti-CD2/CD3/CD28 beads, as well as the number of interferon (IFN)-γ-secreting T cells after stimulation, were measured at different time points of the study. Serum cytokine levels and anti-idiotypic antibody response to itolizumab were also evaluated. Additionally, lymphocyte infiltration and epidermis hyperplasia were studied in five patients. A significant reduction in T cell proliferation capacity and number of IFN-γ-producing T cells was found in treated patients. Serum levels of interleukin-6, tumor necrosis factor and IFN-γ showed an overall trend toward reduction. No anti-idiotypic antibody response was detected. A significant reduction in the epidermis hyperplasia was observed in analyzed patients. These results support the relevance of the CD6 molecule as a therapeutic target for the treatment of this disease.Keywords
This publication has 84 references indexed in Scilit:
- Sleep Loss and Cytokines Levels in an Experimental Model of PsoriasisPLOS ONE, 2012
- Anticorps anti-médicament, auto-anticorps et traitements biologiques du psoriasisAnnales de Dermatologie et de Vénéréologie, 2012
- Serum Cytokine Profile in Psoriasis-A Case–Control Study in a Tertiary Care Hospital from Northern IndiaIndian Journal of Clinical Biochemistry, 2011
- CD6 synergistic co-stimulation promoting proinflammatory response is modulated without interfering with the activated leucocyte cell adhesion molecule interactionClinical and Experimental Immunology, 2010
- Rationale for Targeting CD6 as a Treatment for Autoimmune DiseasesArthritis, 2010
- Cell type-specific regulation of IL-10 expression in inflammation and diseaseImmunologic Research, 2010
- Multiple sclerosis susceptibility alleles in African AmericansGenes & Immunity, 2009
- PsoriasisNew England Journal of Medicine, 2009
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)The Lancet, 2008
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)The Lancet, 2008